Korro Bio (KRRO) Price & Analysis

Compare

484 Followers

KRRO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$10.29 - $98.00

Previous CloseN/A

Volume28.02K

Average Volume (3M)223.29K

Market Cap

$381.83M

Enterprise Value$64.56M

Total Cash (Recent Filing)$96.36M

Total Debt (Recent Filing)$44.63M

Price to Earnings (P/E)―

Beta3.13

Next Earnings

Nov 18, 2025

EPS Estimate

-2.59

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.74

Shares Outstanding9,390,903

10 Day Avg. Volume186,791

30 Day Avg. Volume223,289

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.17

Enterprise Value/Revenue10.28

Enterprise Value/Gross Profit15.31

Enterprise Value/Ebitda-0.68

Forecast

1Y Price Target

$107.33

Price Target Upside163.97% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Commercial OpportunityThe lead program KRRO-110 aims to treat AATD and presents a significant commercial opportunity due to high unmet need and lack of approved disease-modifying therapies.

RNA Editing PotentialRNA editing holds significant potential based on preclinical data and Korro is one of the leaders in the field.

Safety And EfficacyKRRO-110 dosing was safely completed in ~5 SAD HV cohorts, further derisking KRRO-110 LNP safety, given that the assessed doses are likely therapeutically active in AATD patients.

Bears Say

Dilution RiskPossible long-term dilution risk is a concern for Korro Bio, Inc.

Price Target AdjustmentThe price target for Korro Bio, Inc. has been lowered to $90.

Risks And DelaysRisks include delays in advancing pipeline candidates into and through clinical assessment and failure to generate favorable clinical data from ongoing programs.

Korro Bio News

Korro Bio management to meet with Piper Sandler

Meeting to be held in New York on September 30 hosted by Piper Sandler. Published first on TheFly...

6d ago

KRRO

Korro Bio’s Promising RNA Editing Advances and Market Potential Highlighted by Buy Rating

Korro Bio, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas Biliouris from...

12d ago

KRRO

Korro Bio’s KRRO-110: Promising Safety, Efficacy, and Commercial Potential Drive Buy Rating

BMO Capital analyst Kostas Biliouris maintained a Buy rating on Korro Bio yesterday and set a price target...

2M ago

KRRO

Korro Bio price target lowered to $90 from $100 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Korro Bio (KRRO) to $90 from $100 and keeps a...

2M ago

KRRO

Korro Bio Advances RNA Editing Programs in Q2 2025

Korro Bio, Inc. ( ($KRRO) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

KRRO

Korro Bio reports Q2 EPS ($2.74), consensus ($2.59)

Reports Q2 revenue $1.46M, consensus $406.9k. Ram Aiyar, Ph.D., CEO and President of Korro, said, “Throughout the second...

2M ago

KRRO

Buy Rating for Korro Bio Driven by Promising KRRO-110 and Orphan Drug Designation

Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Korro Bio, retaining the price target of...

2M ago

KRRO

Korro Bio receives European Medicines Agency granted ODD for KRRO-110

Korro Bio (KRRO) announced that it has been granted orphan drug designation, ODD, by the European Medicines Agency,...

2M ago

KRRO

Korro Bio management to meet with Piper Sandler

Meeting to be held on July 14 hosted by Piper Sandler. Published first on TheFly – the ultimate...

3M ago

KRRO

Korro Bio Elects New Directors at Annual Meeting

Korro Bio ( ($KRRO) ) has provided an update. At the 2025 annual meeting held on June 11,...

4M ago

KRRO

Korro Bio price target lowered to $90 from $155 at Oppenheimer

Oppenheimer lowered the firm’s price target on Korro Bio (KRRO) to $90 from $155 and keeps an Outperform...

5M ago

KRRO

Korro Bio Reports Q1 2025 Financial Results

Korro Bio, Inc. ( ($KRRO) ) has released its Q1 earnings. Here is a breakdown of the information...

5M ago

KRRO

Korro Bio price target lowered to $53 from $130 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Korro Bio (KRRO) to $53 from $130 and keeps a...

5M ago

KRRO

Korro Bio price target lowered to $100 from $115 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Korro Bio (KRRO) to $100 from $115...

5M ago

KRRO

KRRO FAQ

What was Korro Bio’s price range in the past 12 months?

Korro Bio lowest stock price was $10.29 and its highest was $98.00 in the past 12 months.

What is Korro Bio’s market cap?

Korro Bio’s market cap is $381.83M.

When is Korro Bio’s upcoming earnings report date?

Korro Bio’s upcoming earnings report date is Nov 18, 2025 which is in 50 days.

How were Korro Bio’s earnings last quarter?

Korro Bio released its earnings results on Aug 12, 2025. The company reported -$2.74 earnings per share for the quarter, missing the consensus estimate of -$2.565 by -$0.175.

Is Korro Bio overvalued?

According to Wall Street analysts Korro Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Korro Bio pay dividends?

Korro Bio does not currently pay dividends.

What is Korro Bio’s EPS estimate?

Korro Bio’s EPS estimate is -2.59.

How many shares outstanding does Korro Bio have?

Korro Bio has 9,390,903 shares outstanding.

What happened to Korro Bio’s price movement after its last earnings report?

Korro Bio reported an EPS of -$2.74 in its last earnings report, missing expectations of -$2.565. Following the earnings report the stock price went up 6.246%.

Which hedge fund is a major shareholder of Korro Bio?

Currently, no hedge funds are holding shares in KRRO

Korro Bio Stock Smart Score

Outperform

Fundamentals

Return on Equity

-58.34%

Trailing 12-Months

Asset Growth

-27.71%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Korro Bio

Korro Bio, Inc. is a biotechnology company focused on the development of RNA editing technologies to treat a wide array of genetic diseases. The company operates in the biopharmaceutical sector, leveraging its proprietary platform to create transformative therapies that can precisely edit RNA to correct mutations at the RNA level. Korro Bio's core products include its pipeline of RNA editing therapies aimed at addressing unmet medical needs across multiple therapeutic areas.

Korro Bio (KRRO) Earnings & Revenues

Historic Earnings Reports

KRRO Stock 12 Month Forecast

Average Price Target

$107.33

▲(163.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","148":"$148","43.75":"$43.8","78.5":"$78.5","113.25":"$113.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":147,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$147.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":107.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$107.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$85.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,43.75,78.5,113.25,148],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.2,31.799999999999997,41.4,51,60.599999999999994,70.2,79.8,89.4,99,108.6,118.2,127.8,137.39999999999998,{"y":147,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.2,28.748461538461537,35.29692307692308,41.84538461538462,48.393846153846155,54.94230769230769,61.49076923076923,68.03923076923077,74.58769230769231,81.13615384615385,87.68461538461538,94.23307692307692,100.78153846153846,{"y":107.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.2,27.03076923076923,31.86153846153846,36.69230769230769,41.52307692307692,46.35384615384615,51.184615384615384,56.01538461538462,60.84615384615384,65.67692307692307,70.50769230769231,75.33846153846153,80.16923076923077,{"y":85,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":43.49,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.72,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.16,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.8,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.77,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >